A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials ...

Pursuing the worthy goal of reforming drug pricing requires a more radical change to the pharmaceutical industry.

Excessive crying or crying without any reason happens mostly due to various health-related health conditions like depression, stress, PBA, and even diabetes. Many times, side effects of various ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

GLP-1 drugs were originally intended to control their blood sugar. Since then, they’ve shown promise in countering cardiovascular disease, hypertension, Parkinson disease, and substance use ...

Nearly 5 million Americans with diabetes would qualify to use a GLP-1 receptor agonist for primary stroke prevention but few ...

“It’s a disease that’s characterized by motion but then can take motion away, so you have to keep moving,” said Ryan Dunahue, who was diagnosed with young-onset Parkinson’s disease at age 4 ...

Exclusive: OpenEvidence aims to be ‘Disney+’ with new JAMA deal. OpenEvidence this morning announced it has a new multi-year ...

Take a fascinating look back at the science and technology advances that shaped medicine’s past and will define its future.

Research at Harvard—from medicine to technology to education and business—touches countless lives, moving us closer to ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.